Open in interactive viewer → charts, metric popovers & call review

Cerenome: $1.55M of Gross Billings, $100K of Cash, and a Radiopharmaceutical That Just Broke Its Own Ceiling

A $5.4M market cap is betting a diagnostics launch collects — while the pipeline asset delivers a genuinely clean fractionation signal
CNSY · Earnings Call · 2026-11-16

The only number that mattered this quarter was $0.1 million

Cerenome reported third-quarter net diagnostic revenue of $0.7 million on 222 submitted claims and roughly $1.55 million of gross charges at list price. Then, in October, it collected about $0.1 million in cash. That is the whole story of the equity in three figures: a company asking the market to underwrite a commercial ramp using a metric it literally cannot yet convert into revenue. CFO Andrew Sims was unusually plain about it: “until we have payer experience in the collections history, we will use gross billings as the logical way to communicate business progress ahead of a revenue or cash number” — Andrew Sims, Chief Financial Officer · 2026-11-16. That is a fair thing for a launch-stage diagnostics company to say once. It is also a confession that the $10 million to $12.5 million annualized gross billings run rate the company reaffirmed for year-end 2026 is a list-price construct with an unknown collection coefficient attached. Management helpfully volunteers that early collections are landing at roughly 50% of billings — a number that will drift as payer mix, contractual adjustments and the new molecular codes get worked through. The call's vocabulary gives the inflection away. Freshly prominent in the quarter's keyword set are collection history, collections, billing and claims — billing-process words, not discovery words. The keyword with the highest momentum on the whole call was tumor cell enumeration, the lead CNSide diagnostic assay. This is a company whose narrative has migrated from the lab bench to the revenue cycle, and the market has not been given a number to value that migration with.

Medicare slipped a year, coverage doubled

Russ Bradley laid out the market-access scorecard with more specificity than this company usually offers: 26 institutions and 45 providers ordering, up from 13 at the start of the year; 34 more institutions in the onboarding queue; 100 signed access agreements; 512 tumor cell enumeration tests year-to-date; and “approximately 190 million covered lives or about 80% of U.S. private payer coverage” — Russell Bradley, Chief Commercial Officer · 2026-11-16. That last figure is roughly triple the ~67 million lives contracted at the start of 2026 and comfortably clears the 150 million target set in January. Aetna is the first national agreement to include contracted rates for both enumeration and the newly launched molecular profile, which is the strategically important bit — one CSF draw, two billable tests. But the reimbursement headline moved. Marc Hedrick's prepared line was “We also remain on track to secure Medicare reimbursement in the first half of the year” — Marc Hedrick, Chief Executive Officer · 2026-11-16, and Bradley clarified the operative date as the first half of 2027. The proprietary billing code took effect July 1 and enrollment is complete, so the delay is process, not policy — but it means the single largest payer in the system contributes nothing to the 2027 gross billings bridge management is sketching. That is not a company-unique worry. Among the reporters in this window, Medicare reimbursement was being negotiated by diagnostics peer LUCD, and the broader small-cap med-tech group was trading around coverage decisions — the Kidney Care National plan popped up at RMTI, HNSA.ST and RMR. Reimbursement timing, not clinical data, is the shared fault line across this cohort.

What actually worked: fractionation

Strip away the launch mechanics and the clinical readout was the genuinely new thing on this call. In the ReSPECT-LM multi-dose study, one patient received three doses of 26.4 millicuries for 79.2 millicuries cumulative — above the 66 millicurie maximum feasible single dose from Phase I — with no dose-limiting toxicity. The single prior signal of dose limiting toxicity in the Phase I was marrow suppression.

The bottom line is that we've broken the ceiling from Phase I. And to date so far, feel very confident we could administer ultimately more radiation, get and deliver more absorbed radiation and avoid any of the dose-limiting toxicities that are known for not just REYOBIQ but any radiopharmaceutical.

Eric Daniels, Chief Medical Officer · 2026-11-16
Dosimetry was stable dose-to-dose, with radiation per millicurie varying only 8% across repeats, and bone marrow exposure stayed low — the mechanism that makes the ceiling-break credible rather than merely anecdotal. Of the first 10 patients, “Only 1 of 10 patients had leptomeningeal progression through MRI documentation at 7.5 months” — Eric Daniels, Chief Medical Officer · 2026-11-16, and several patients' CSF tumor counts fell to zero and stayed there. That is descriptive, not powered, and management said so. It is nonetheless the first time this asset has produced a dose-density argument that a partner or a financier can underwrite. On glioblastoma, completing enrollment was achieved — but at 32 patients rather than the planned 34, because, as Eric Daniels put it, closing at 32 would have "minimal effect on the power of the planned analysis." Trimming two patients to shorten a timeline is the tell of a company managing cash, not just science. Top-line data for both GBM and the LM dose-optimization study now land mid-2027, with a randomized Phase IIb in LM in the second half of 2027.

A $5.4 million equity and a $20 million option

Here is where the narrative meets arithmetic. Cerenome's entire market capitalization is roughly $5.4 million — under two quarters of the company's own spend. The fundamentals as filed show a net loss of about $9 million in the latest reported quarter and an operating loss of roughly the same size, against effective net cash of $15 million, down 44% from its 2026Q1 peak. The cash runway reading of 1.2 quarters is the single most uncomfortable figure in the deck. Management's answer is the September royalty and financing facility of up to $20 million, plus the roughly $4 million raised in October. Sims was explicit that “This combination, if fully accessed, extends the runway into 2028” — Andrew Sims, Chief Financial Officer · 2026-11-16 — the conditional is doing heavy lifting. And the path to self-funding rests on a doubling: “we expect that gross billing revenue number to double in 2027” — Andrew Sims, Chief Financial Officer · 2026-11-16 to $20-25 million, versus a CNSide cash burn of about $10 million a year, which is how the company gets to positive contribution late in 2027. Every step of that bridge — patient monitoring repeat testing (nearly 1 in 4 patients retested; 23 tested four or more times), the expanding menu, the four-person field team ramping in Q1 — is plausible and none of it is yet proven in cash. The honest read: the science de-risked this quarter and the commercial model did not. Cerenome has told investors to value a billings construct at list while it builds a collection history from a standing start, funded by a facility it has not fully drawn and an equity base smaller than one quarter of R&D plus SG&A. The stock is already priced as an option. The mid-2027 REYOBIQ readouts are the only catalyst that can reprice it on something other than a collection rate.